Does Rallies show 13F holders for CNTA?

Yes. Rallies tracks hedge fund and 13F ownership data for CNTA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CNTA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CNTA. It does not provide personalized investment advice.

CNTA (Centessa Pharmaceuticals plc American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Centessa Pharmaceuticals plc American Depositary Shares (CNTA) is a publicly traded Healthcare sector company. As of May 20, 2026, CNTA trades at $39.55 with a market cap of $6.13B and a P/E ratio of -27.22. CNTA moved +0.18% today. Year to date, CNTA is +72.68%; over the trailing twelve months it is +201.14%. Its 52-week range spans $9.60 to $40.26. Analyst consensus is neutral with an average price target of $42.40. Rallies surfaces CNTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CNTA stock?

Hedge funds tracked by Rallies that own CNTA include Pentwater Capital, Farallon Capital, Maverick Capital, and Fortress Investment. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Centessa Pharmaceuticals plc American Depositary Shares.

CNTA Key Metrics

Key financial metrics for CNTA
Metric	Value
Price	$39.55
Market Cap	$6.13B
P/E Ratio	-27.22
EPS	$-1.46
Dividend Yield	0.00%
52-Week High	$40.26
52-Week Low	$9.60
Volume	814.63K
Avg Volume	0
Revenue (TTM)	$15.00M
Net Income	$-197.53M
Gross Margin	0.00%

Top Hedge Funds Holding CNTA

Pentwater Capital holds 8.17M shares of CNTA, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 4.81M shares of CNTA, changed -10.56% as of Mar 31, 2026.
Maverick Capital holds 1.85M shares of CNTA, changed +12.82% as of Mar 31, 2026.
Fortress Investment holds 20.00K shares of CNTA, changed +0.00% as of Mar 31, 2026.

Latest CNTA News

Law Firm Challenges Centessa $38 Cash Plus Up to $9 CVR Sale to Lilly — May 12, 2026
Eli Lilly to Acquire Centessa for $7.8B Including $38 Cash, $9 CVRs — Apr 2, 2026
Centessa Pharmaceuticals Shares Soar 44.4% to $39.90 on $6.3B Eli Lilly Deal — Mar 31, 2026
Eli Lilly to Acquire Centessa for $38 per Share, Up to $7.8B — Mar 31, 2026

Recent CNTA Insider Trades

Anderson Karen M. sold 41.08K (~$1.24M) on Mar 26, 2026.
Weinhoff Gregory M sold 24.00K (~$719.94K) on Mar 26, 2026.
Anderson Karen M. sold 10.04K (~$282.21K) on Mar 17, 2026.

CNTA Analyst Consensus

10 analysts cover CNTA: 0 strong buy, 1 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $42.40.

Common questions about CNTA

Who owns CNTA stock?: Hedge funds tracked by Rallies that own CNTA include Pentwater Capital, Farallon Capital, Maverick Capital, and Fortress Investment. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Centessa Pharmaceuticals plc American Depositary Shares.
Does Rallies show 13F holders for CNTA?: Yes. Rallies tracks hedge fund and 13F ownership data for CNTA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CNTA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CNTA. It does not provide personalized investment advice.